Global Stem Cell Industry Development: Regenerative Medicine Innovation and China’s Rise in Advanced Cell Therapies
View our Complimentary Blue Book
Stem cell therapy, as an advanced form of cell therapy that harnesses the unique biological properties of stem cells—including self-renewal and multilineage differentiation—stands at the forefront of global regenerative medicine. By repairing and regenerating damaged cells, tissues, or organs through ex vivo preparation and transplantation, stem cell therapies offer transformative potential for degenerative diseases, autoimmune disorders, and organ damage. Driven by surging global clinical demand, breakthroughs in iPSC reprogramming, gene editing, standardized cell manufacturing, and organoid modeling, the stem cell industry is entering a critical stage of transition from basic research to standardized clinical translation and commercialization. Supported by technological upgrading, expanded regulatory frameworks, and continuous capital inflow, the global stem cell market is expanding rapidly. Meanwhile, China’s stem cell industry, backed by a huge patient population, enhanced local R&D capabilities, and accelerated industrialization, is increasingly becoming a key growth engine and emerging force in the global stem cell landscape.
Download this complimentary Blue book to discover:
Global and China Stem Cell Industry and Future Outlook:
An in-depth analysis of the global and Chinese stem cell industry, covering epidemiological drivers, growth potential, competitive patterns, and regional development differences. The global stem cell therapeutics market was valued at U.S. $0.12 billion in 2024 and is projected to reach U.S. $11.01 billion by 2030. China’s stem cell drug market entered a substantive growth phase in 2025 and is projected to reach RMB 14.09 billion by 2030, revealing huge unmet needs and long-term growth logic.
Clinical Applications and Unmet Needs:
A forward-looking assessment focusing on core clinical pain points across major indications including graft-versus-host disease, heart failure, Parkinson’s disease, knee osteoarthritis, stroke, liver cirrhosis and liver failure, idiopathic pulmonary fibrosis, chemotherapy-induced thrombocytopenia, chronic obstructive pulmonary disease, and chronic periodontitis, with an emphasis on disease-modifying potential beyond symptomatic relief.
Regulatory Frameworks and Manufacturing Systems:
Analysis of global regulatory pathways including the U.S. FDA (RMAT, Breakthrough Therapy, Fast Track), EU EMA (ATMP, PRIME), Japan PMDA/MHLW (dual-track with conditional and time-limited approval), and China NMPA/NHC (dual-track under Decree No. 818 and Decree No. 828), alongside the establishment of integrated GMP-compliant manufacturing, cell banking, automated production, and quality control systems.
Profiles of Leading Stem Cell Enterprises Worldwide:
Showcasing global and Chinese stem cell pioneers and their core technologies, product pipelines and commercialization layout.
Default PDF Reader
Register to Download the Blue Book To-go
60 YEARS OF INSIGHTS
Our Global Initiatives
ABOUT THE ANALYST
Qian Li
About Our Firm
Frost & Sullivan